Worldwide Country Situation Analysis: Response to Antimicrobial Resistance. WHO. (2015)

immage

A survey was conducted in countries in all six WHO regions and focused on the building blocks that are considered prerequisites to combat antimicrobial resistance: a comprehensive national plan, laboratory capacity to undertake surveillance for resistant microorganisms, access to safe, effective antimicrobial medicines, control of the misuse of these medicines, awareness and understanding among the general public and effective infection prevention and control programmes. 


Keywords: drug resistance, microbial, infection control, surveillance

 


Download Full report and Summary report

An Ambitious Treatment Target to Help End the AIDS Epidemic. UNAIDS. (2014)

immage

HIV treatment is a unique tool in the AIDS response, preventing illness and death, averting new infections and saving money. As hopes for ending the AIDS epidemic depend  in large measure on the world’s ability to provide HIV treatment to all who need it, in a rights-based approach, final targets for universal treatment access are critical.

 

Keywords: HIV, coverage, testing, antiretroviral therapy (ART), antiretroviral drugs (ARV), key populations, 90-90-90

Download Publication

A Review of the Delamanid Patent Landscape: A Scoping Report. Amin T. (2014)

immage

Delamanid was discovered via a screening programme carried out by Otsuka. The compound belongs to the nitroimidazole class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was already reported in 1993.4 Indeed, various 5- and 2-nitroimidazoles and 5-nitrofurans were already known to be effective against a variety of protozoan and bacterial infections in humans and animals. For example, the published international patent application WO 97/01562 previously disclosed a 6-nitro- 1,2,3,4-tetrahydro[2,1-b]-imidazopyran compound with bactericidal action in vitro to mycobacterium TB.

 

Keywords: HIV, TB, pediatric, testing, drugs, treatment

Download Publication

The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health. Bhardwaj K and Oh C. (2014)

immage

The objective of this report is to provide an analysis of the provisions in the proposed TPPA in order to obtain a clearer understanding of their implications. It is hoped that the report will also be a useful resource for other stakeholders in the public health field.

The report analyses the key negotiating issues in the USA’s proposals (widely considered to be the basic negotiation text for the TPPA) which are likely to have an impact on access to medicines and public health.


Keywords: HIV, health, access, medicines, financing, 

Download Publication

Policy Brief: Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. WHO (2014)

immage

This policy brief provides an overview of key findings, data and figures of the new consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. In addition, it offers an overview of the comprehensive package on interventions and a table summarizing WHO recommendations concerning key populations.

 

Keywords: HIV, men who have sex with men (MSM), people who inject drugs (PWID), sex workers, transgender, testing, treatment

Download Publication

A Review of the PA-824 Patent Landscape: A Scoping Report. Amin T. (2014)

immage

Like delamanid, PA-824 belongs to the nitroimidazoles class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was reported as early as 1993.3 PA-824 was discovered by Patho- Genesis Corporation, which was subsequently acquired by Chiron Corporation. Novartis AG acquired Chiron Corporation in 2006.

PA-824 is a pro-drug, which requires reductive activation of an aromatic nitro group before it becomes effective against TB bacteria.4 Pre-clinical studies have demonstrated that PA-824 has potent bactericidal and sterilizing effects against DS-TB and MDR-TB. PA-824 has also been shown to be active against latent TB bacteria.

 

Keywords: TB, bacteria, orphan, drug, access

Download Publication

HIV Medicines Technology and Market Landscape - 1st Edition. UNITAID. (2014)

immage

Access to appropriate antiretroviral therapy (ART) is vital to prevent HIV morbidity and mortality, and high ART coverage also promotes HIV prevention by lowering the amount of virus circulating in people within a particular setting or population. The World Health Organization (WHO) released new treatment recommendations in June 2013 that raise the CD4 cell count threshold for ART initiation for most people (from 350 to 500 cells/mL) and expand the number of populations that should receive treatment irrespective of their immune status. These changes have substantially increased the number of people eligible for ART. At the end of 2012, almost 10 million people were receiving ART in low- and middle-income countries, or about 34% of the total eligible population under the 2013 WHO treatment guidelines (28.6 million). The access level in children was falling behind at an estimated 20% of the total paediatric population in need of ART; while 647 000 children were receiving ART as of December 2012, an additional 2.6 million children were eligible for ART under current WHO treatment guidelines, but not receiving it.


Keywords: HIV, ARV, treatment, infant, children, medicines

Download Publication

Specifications and Quantities for Efficient Procurement of Essential Equipment and Laboratory Commodities for HIV. WHO. (2014)

immage

WHO, with support from Centers for Disease Control and Prevention (CDC), developed the present tool on specifications and quantities for efficient procurement of essential equipment and laboratory commodities for HIV.

The ultimate purpose of the tool is to facilitate the efficient procurement of laboratory equipment and laboratory commodities required to:

   - perform HIV diagnostic tests in adults, adolescent and children;
   - monitor treatment outcomes in patients on antiretroviral therapy.

Keywords: HIV infections, diagnosis, anti-retroviral agents, treatment outcome, technology medical

Download Publication

A Review of the SQ-109 Patent Landscape: A Scoping Report. Amin T. (2014)

immage

SQ109 falls into the class of drugs known as ethylenediamines. The compound was discovered by Sequella Inc in collaboration with the United States National Institutes of Health (NIH). A solid phase method was developed to synthesize more than 63 000 compounds based on the 1,2-ethylenediamine structure of ethambutol. Using a high-throughput screening assay, compounds were identified that affected genes activated during cell membrane repair by the TB bacilli.


Keywords: HIV, TB, drugs, treatment, diagnosis, access

Download Publication

Policy Brief: Transition to New HIV Treatment Regimens - Procurement and Supply Chain Management Issues. WHO. (2014)

immage

This policy brief provides advice on a phased approach to transitioning to new HIV treatment regimens, as recommended by the World Health Organization (WHO). The target audience includes implementing partners, antiretroviral therapy (ART) programme managers, procurement managers and other relevant parties. The ultimate purpose is to ensure a continuous supply of antiretroviral (ARV) drugs, and ensure rapid and efficient implementation of the new WHO ARV guidelines, with smooth transitioning to new recommended ARV regimens, while reducing the wastage or expiry of products that are no longer recommended. 

Keywords: HIV infection, pregnant, breastfeeding, treatment, medicines

Download Publication

Pages

database
Highlighted publications
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Get_on_the_Fast-Track_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NEC_HIV_July-Oct-AIDSreg2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Response_Progress_Reporting_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_AIDS_by_the_numbers_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Biomedical_AIDS_research_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_cities_ending_the_aids_epidemic_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Factsheets.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_Report_Punjab_2014_0.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Integrating_collaborative_TB_and_HIV_services_within_a_comprehensive_package_of_care_for_PWID_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_IBBS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/India_HSS_report_2014-15.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/The_negative_impact_of_drug_control_on_public_health_2015.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_young_people_drugs_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Death_Penalty_for_Drug_Offences_Global_Overview_2015.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Transforming_our_world_2015_UN.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Consolidated_Strategic_Information_Guidelines_for_HIV_in_Health_Sector_2015.pdf
Calendar of events
Apr
7
(7 Apr - 7 Apr)
May
17
(17 May - 17 May)
Jul
28
(28 Jul - 28 Jul)